These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16160637)
21. [Risperidone and cerebrovascular adverse effects in elderly patients with dementia]. Formiga F; Fort I; Pérez-Castejón JM; Ruiz D; Duaso E; Riu S Rev Clin Esp; 2006 Sep; 206(8):411-2; author reply 412-3. PubMed ID: 16863635 [No Abstract] [Full Text] [Related]
22. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855 [TBL] [Abstract][Full Text] [Related]
23. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
24. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974 [TBL] [Abstract][Full Text] [Related]
25. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678 [TBL] [Abstract][Full Text] [Related]
26. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. Smith RC; Chua JW; Lipetsker B; Bhattacharyya A J Clin Psychiatry; 1996 Oct; 57(10):460-6. PubMed ID: 8909332 [TBL] [Abstract][Full Text] [Related]
28. Recovery in schizophrenia: focus on neurocognitive functioning. Zaytseva Y; Gurovich IY; Goland E; Storozhakova YA Psychiatr Danub; 2012 Sep; 24 Suppl 1():S172-5. PubMed ID: 22945216 [TBL] [Abstract][Full Text] [Related]
29. Quality of life and atypical antipsychotics. Rudnick A J Clin Psychopharmacol; 1998 Oct; 18(5):424-5. PubMed ID: 9790165 [No Abstract] [Full Text] [Related]
30. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders? Croarkin PE; Daskalakis ZJ J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):949-51. PubMed ID: 22917209 [No Abstract] [Full Text] [Related]
31. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G; Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797 [TBL] [Abstract][Full Text] [Related]
32. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. McClure MM; Koenigsberg HW; Reynolds D; Goodman M; New A; Trestman R; Silverman J; Harvey PD; Siever LJ J Clin Psychopharmacol; 2009 Aug; 29(4):396-8. PubMed ID: 19593186 [No Abstract] [Full Text] [Related]
33. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138 [No Abstract] [Full Text] [Related]
34. Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder. Dias VV; Brissos S; Gorman JM J Psychiatr Pract; 2006 Sep; 12(5):327-31. PubMed ID: 16998423 [No Abstract] [Full Text] [Related]
35. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Cho SJ; Yook K; Kim B; Choi TK; Lee KS; Kim YW; Lee JE; Suh S; Yook KH; Lee SH Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):208-11. PubMed ID: 21095214 [TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. Schreiber S; Klag E; Gross Y; Segman RH; Pick CG Int Clin Psychopharmacol; 1998 Nov; 13(6):273-5. PubMed ID: 9861578 [TBL] [Abstract][Full Text] [Related]
37. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Lindenmayer JP; Khan A Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275 [TBL] [Abstract][Full Text] [Related]
38. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Lee SW; Lee JG; Lee BJ; Kim YH Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705 [TBL] [Abstract][Full Text] [Related]
39. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. Addington J; Addington D Can J Psychiatry; 1997 Nov; 42(9):983. PubMed ID: 9429073 [No Abstract] [Full Text] [Related]
40. Recent advances in treating cognitive impairment in schizophrenia. Galletly C Psychopharmacology (Berl); 2009 Jan; 202(1-3):259-73. PubMed ID: 18766331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]